Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing ... announced that it has initiated dosing in a Phase ... oral therapy for the treatment of HCV infection. This study ... designed to assess both the safety and antiviral efficacy ... for the treatment of chronic HCV infections and is ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... DIEGO , May 23, 2013 ... today announced the appointment of David ... Mr. Ramsay was most recently Vice President, Corporate ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO )     "With his established financial ... experience gained by working in our commercial group ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... SEATTLE, May 2, 2011 CMC Biologics, a ... Copenhagen, Denmark and Seattle, Washington USA, announced today ... at its Chief Executive Officer. CMC Biologics, a ... world class, fully integrated, biopharmaceutical process development and ...
... SAN DIEGO, May 2, 2011 Volcano Corporation (NASDAQ: ... of precision intravascular diagnosis and therapy guidance tools designed ... disease, said today that it will be participating in ... May 10. The presentation by John Dahldorf, ...
Cached Medicine Technology:CMC Biologics Announces Appointment of New CEO 2
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 “Talk. ... (PSA) campaign that empowers parents to talk to children ... of underage drinking, was launched today by the Substance ... The kickoff occurred in conjunction with SAMHSA’s 2013 National ... of, and action around, substance abuse and mental health ...
(Date:5/23/2013)... Live Lead Pros , with its ... business lead solution via its smart solution for ... features Free Web Based Account Management, Database Usage, ... "Automatic Transfer Retry". The company has recently announced ... system. , Its Free Database Usage offers their ...
(Date:5/23/2013)... anti-cancer drug about to be tested in a clinical ... possible treatment for Alzheimer,s disease has failed to work ... Alzheimer,s patients, according to results of a study by ... professor of neuroscience affiliated with the Evelyn F. and ... Florida, emphasized the importance of verifying promising research results ...
(Date:5/23/2013)... characterized as "triple negative" carries a poor prognosis, with ... kill the cancer cells the way it,s supposed to. ... cells don,t respond to chemotherapy, and identifies a mechanism ... Dr. Shawn Li, PhD, and his team at Western,s ... protein called Numb functions to promote the death of ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
Breaking Medicine News(10 mins):Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3
... taken by European governments and healthcare authorities ... at improving efficiency levels and reducing expenditures. ... is proving to be a major challenge.(Logo: ... from governments across Europe to install infection ...
... Programs Supported by a Grant from Otsuka America ... quality of care and increasing awareness of and ... communities are all values held by the 2009 ... for Advancing Minority Mental Health.The awards, presented by ...
... 5 Nutrition 21, Inc. (Nasdaq: NXXI ), ... manage blood sugar levels, improve cardiovascular health, enhance memory and ... to the opening of the market - on Tuesday, May ... ended March 31, 2009. The Company has scheduled a conference ...
... Market for Women,s Health Devices Worth $2.1 Billion in ... research reports by iData Research ( www.idataresearch.net ) - ... firm - the U.S. market for female sterilization devices ... market, transcervical sterilization devices, which grew over 54% in ...
... $19.7 Million -- Same-Store Sales Increased 1.1% -- Net Cash ... Loss Improved 18.0% to $17.2 Million - , NEW YORK, ... results for the first quarter ended March 28, 2009. Key ... Adjusted FIFO EBITDA increased 7.8% to $19.7 ...
... coli, K. pneumoniae and P. aeruginosa Directly from ... Hours Sooner Than Conventional Methods to Help Clinicians ... Gram-Negative Bloodstream InfectionsWOBURN, Mass., and VEDBAEK, Denmark, May ... 510(k) clearance for EK/ P. aeruginosa PNA ...
Cached Medicine News:Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 2Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 3Health News:American Psychiatric Foundation Names 2009 Recipients of Awards for Advancing Minority Mental Health 4Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:U.S. Market for Female Sterilization Devices to Grow 36% in 2009 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 3Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 4Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 5Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 6Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 7Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 8Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 9Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 10Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 11Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 12Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 13Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 14Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 15Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 2Health News:AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R) 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: